Cyclerion Therapeutics (NASDAQ:KRSA) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research note issued to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $43.00 price target on the stock.

KRSA has been the topic of several other reports. UBS Group assumed coverage on Cyclerion Therapeutics in a report on Friday, September 11th. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Cyclerion Therapeutics currently has an average rating of “Buy” and a consensus target price of $49.00.

Cyclerion Therapeutics Stock Performance

Shares of KRSA stock opened at $31.23 on Monday. Cyclerion Therapeutics has a 52 week low of $7.19 and a 52 week high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.